DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Biosimilars | Market Events and Forecast Landscape – Overview of Biosimilar Forecasts | 2022
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
Biosimilars | Market Events and Forecast Landscape – Forecast Methodology and General Market Assumptions | 2022
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
Epilepsy – Current Treatment – Current Treatment: Physician Insights – Epilepsy (US)
For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…
Sickle Cell Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2022
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to several…
Biomarkers in Oncology | Access & Reimbursement | US | Non-Small-Cell Lung Cancer, Breast Cancer, and Colorectal Cancer | 2022
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Parkinson’s Disease – Access & Reimbursement – Access & Reimbursement – Parkinson’s Disease (US)
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NHL patient populations covering 171 countries and more than 99% of…
